Show simple item record

Authordc.contributor.authorWolfe, G. I. 
Authordc.contributor.authorKaminski, H. J. 
Authordc.contributor.authorAban, I. B. 
Authordc.contributor.authorMinisman, G. 
Authordc.contributor.authorKuo, H. C. 
Authordc.contributor.authorMarx, A. 
Authordc.contributor.authorStröbel, P. 
Authordc.contributor.authorMazia, C. 
Authordc.contributor.authorOger, J. 
Authordc.contributor.authorCea, J. G. 
Authordc.contributor.authorHeckmann, J. M. 
Authordc.contributor.authorEvoli, A. 
Authordc.contributor.authorNix, W. 
Authordc.contributor.authorCiafaloni, E. 
Authordc.contributor.authorAntonini, G. 
Authordc.contributor.authorWitoonpanich, R. 
Authordc.contributor.authorKing, J. O. 
Authordc.contributor.authorBeydoun, S. R. 
Authordc.contributor.authorChalk, C. H. 
Authordc.contributor.authorBarboi, A. C. 
Authordc.contributor.authorAmato, 
Admission datedc.date.accessioned2019-03-18T11:54:54Z
Available datedc.date.available2019-03-18T11:54:54Z
Publication datedc.date.issued2016
Cita de ítemdc.identifier.citationNew England Journal of Medicine, Volumen 375, Issue 6, 2018, Pages 511-522
Identifierdc.identifier.issn15334406
Identifierdc.identifier.issn00284793
Identifierdc.identifier.other10.1056/NEJMoa1602489
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/166871
Abstractdc.description.abstractCopyright © 2016 Massachusetts Medical Society. BACKGROUND: Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone. METHODS: We compared extended transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone. Patients 18 to 65 years of age who had generalized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if they had Myasthenia Gravis Foundation of America clinical class II to IV disease (on a scale from I to V, with higher classes indicating more severe disease) and elevated circulating concentrations of acetylcholine-receptor antibody. The primary outcomes were the time-weighted average Quantitative Myasthenia Gravis score (on a scale from 0 to 39, with higher scores indicating more severe disease) over a 3-year period, as assessed by means of
Lenguagedc.language.isoen
Publisherdc.publisherMassachussetts Medical Society
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
Sourcedc.sourceNew England Journal of Medicine
Keywordsdc.subjectMedicine (all)
Títulodc.titleRandomized trial of thymectomy in myasthenia gravis
Document typedc.typeArtículo de revista
dcterms.accessRightsdcterms.accessRightsAcceso Abierto
Catalogueruchile.catalogadorSCOPUS
Indexationuchile.indexArtículo de publicación SCOPUS
uchile.cosechauchile.cosechaSI


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile